Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Appl Opt ; 55(13): 3456-61, 2016 May 01.
Article in English | MEDLINE | ID: mdl-27140356

ABSTRACT

Hamiltonian-based ray-tracing technique with mesh representation is presented for designing large-scale cloaking devices with three-dimensional arbitrary shapes, which have inhomogeneity and anisotropy in their electric permittivity and magnetic permeability. In order to deal with arbitrary shapes, the surfaces of the cloaking devices are represented by triangular meshes. Comparison between the result of cloaking simulations with the mesh representation and those with the rigorous function representation is presented. The numerical results showed that fine-mesh resolution is required for accurate evaluation of cloaking performances.

2.
Dig Liver Dis ; 44(8): 649-54, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22542605

ABSTRACT

BACKGROUND: 6-Mercaptopurine is often used as maintenance therapy in patients with Crohn's disease. However, toxicities like myelosuppression limit its clinical benefit. AIMS: To evaluate the efficacy of elemental diet versus 6-mercaptopurine as maintenance therapy in Crohn's disease. METHODS: Ninety-five eligible patients with Crohn's disease activity index ≤150 were randomly assigned to: 6-mercaptopurine (0.5-1.5mg/kg/day, n=30); Elental as an elemental diet (≥900 kcal/day, n=32); none (control, n=33). In the three groups, patients were and remained on 5-aminosalicylic acid (2250-3000 mg/day). Patients were observed for 2 years and the rate of relapse (Crohn's disease activity index ≥200) was monitored. RESULTS: At 24 months, the fractions of patients who had maintained remission were 60%, 46.9% and 27.2% for 6-mercaptopurine, Elental and the control groups, respectively. Log-rank test showed better efficacy for 6-mercaptopurine (P=0.0041) and Elental (P=0.0348) versus control. No significant difference was found between 6-mercaptopurine and Elental. Further, in the 6-mercaptopurine group, 2 patients experienced liver injury and one developed alopecia. CONCLUSIONS: This 24 months comparison study showed that Elental as maintenance therapy in Crohn's disease patients was as effective as 6-mercaptopurine. Elental should be useful for long-term maintenance therapy in Crohn's disease. This is the first comparison study evaluating nutritional therapy versus 6-mercaptopurine.


Subject(s)
Crohn Disease/diet therapy , Crohn Disease/drug therapy , Food, Formulated , Immunosuppressive Agents/therapeutic use , Mercaptopurine/therapeutic use , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Food, Formulated/adverse effects , Humans , Immunosuppressive Agents/adverse effects , Kaplan-Meier Estimate , Longitudinal Studies , Maintenance Chemotherapy , Male , Mercaptopurine/adverse effects , Mesalamine/therapeutic use , Recurrence , Young Adult
3.
Clin Gastroenterol Hepatol ; 10(8): 879-885.e2, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22542748

ABSTRACT

BACKGROUND & AIMS: Low doses of aspirin can injure the gastric mucosa. It is not clear whether other drugs such as the antiplatelet agent clopidogrel also cause gastric mucosal injury or exacerbate aspirin-induced injury, or whether proton pump inhibitors prevent damage. METHODS: Twenty Japanese subjects with different CYP2C19 genotypes were randomly assigned to groups that were given a low dose of aspirin (100 mg; A), clopidogrel (75 mg; C), low dose of aspirin and clopidogrel (AC), or low dose of aspirin in combination with clopidogrel and rabeprazole (10 mg; ACR) once daily for 7 days. Subjects underwent gastroduodenoscopy and platelet tests on days 3 and 7; gastric mucosal damage was assessed by using the modified Lanza score (MLS). We performed 24-hour intragastric pH monitoring on day 7 of each regimen. We also analyzed the effects of the AC regimen on 30 patients with different CYP2C19 genotypes. RESULTS: Subjects in groups A, C, and AC had significantly higher levels of gastric mucosal damage on days 3 and 7, compared with baseline. The median MLS for the AC group was similar to that of the A group. Helicobacter pylori-negative subjects in the ACR group with different CYP2C19 genotypes had significant differences in MLS, intragastric pH, and platelet function. Gastric mucosal injury was inhibited equally among H pylori-positive subjects in the ACR group. Rabeprazole did not appear to affect platelet function or intragastric pH in subjects given clopidogrel. CONCLUSIONS: Clopidogrel and low doses of aspirin cause a similar degree of gastric mucosal damage. Rabeprazole prevented this damage without reducing the antiplatelet function of clopidogrel. However, its prophylactic effect varies with CYP2C19 genotype in H pylori-negative subjects.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , Anti-Ulcer Agents/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Aspirin/adverse effects , Gastric Mucosa/pathology , Peptic Ulcer/prevention & control , Ticlopidine/analogs & derivatives , Adult , Asian People , Aspirin/administration & dosage , Clopidogrel , Cross-Over Studies , Cytochrome P-450 CYP2C19 , Endoscopy, Gastrointestinal , Female , Genotype , Humans , Male , Rabeprazole , Severity of Illness Index , Ticlopidine/administration & dosage , Ticlopidine/adverse effects , Treatment Outcome , Young Adult
4.
Gan To Kagaku Ryoho ; 39(1): 81-4, 2012 Jan.
Article in Japanese | MEDLINE | ID: mdl-22241356

ABSTRACT

To investigate the effect clinical path of cancer pain treatments for opioid naive patients has on physician practice, a prepost quasi-experimental study was performed. The primary outcome measure was the percentage of patients who received 'recommended pain treatments' during the study periods. We determined the treatment to be the treatment of choice, if the physician 1) ordered a rescue dose, 2) prescribed a laxative, and 3) prescribed antiemetics when starting opioids. The secondary outcome measure was the number of newly consulted patients for our palliative care team. The end-points were measured before and after disseminating the clinical path. The rate of patients receiving recommended pain treatments significantly increased after disseminating the clinical path(p=0.03): 17%(33/18)to 61%(19/31). Patients who received a rescue order, laxative, or antiemetic when starting opioids were: 44% vs. 68%, 77% vs. 90%, and 66% vs. 77%, respectively. The number of patients newly consulting the palliative care team was increased(21 cases to 42 cases/4 month). In conclusion, the clinical path of cancer pain treatments is useful for improving the physician's practice when starting opioids for cancer pain, and might contribute to enhancing palliative care team availability.


Subject(s)
Analgesics, Opioid/administration & dosage , Critical Pathways/standards , Oxycodone/administration & dosage , Pain/drug therapy , Palliative Care , Analgesics, Opioid/adverse effects , Analgesics, Opioid/therapeutic use , Female , Humans , Male , Oxycodone/adverse effects , Oxycodone/therapeutic use
5.
J Surg Res ; 169(2): e137-43, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21612793

ABSTRACT

BACKGROUND: Gastric cancer is one of the major causes of death in Japan. We have previously reported, using biopsy specimens, the usefulness of the 1064 nm near-infrared multichannel Raman spectroscopy (RAS) system as a novel diagnostic modality for gastric cancer. However, our study might not have reflected in vivo use of RAS due to a lack of tissue other than the mucosal layer in the biopsy specimens. Here, we used RAS ex vivo for optical diagnosis of gastric cancer in surgically resected stomach. MATERIALS AND METHODS: A total of 213 Raman spectra were obtained from 12 cancer lesions and their corresponding non-neoplastic areas in 10 stomachs following resection for gastric cancer. To develop optical diagnostic systems for gastric cancer, principal component analysis (PCA) of all the Raman spectra was performed. RESULTS: The averaged Raman spectra of the cancer lesions could be distinguished from those of the non-neoplastic regions. Discrimination analysis of cancer from non-neoplastic regions with 10 principal components revealed that sensitivity, specificity, and accuracy of cancer diagnosis were 73%, 73%, and 72%, respectively. RAS discriminated between differentiated and undifferentiated cancers, early and advanced cancers, as well as T1a (M) and T1b (SM) cancers with high accuracy (98%, 93%, and 98%, respectively). CONCLUSIONS: The 1064 nm near-infrared multichannel RAS system is useful not only for gastric cancer detection, but also for discrimination between differentiated and undifferentiated, as well as early and advanced cancers. RAS could help establish indications for endoscopic treatment by eliminating cancer lesions with an undifferentiated component or submucosal invasion.


Subject(s)
Adenocarcinoma/diagnosis , Spectroscopy, Near-Infrared/methods , Spectrum Analysis, Raman/methods , Stomach Neoplasms/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Biopsy , Cell Differentiation , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Stomach/pathology , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery
6.
Cancer Sci ; 102(4): 883-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21244575

ABSTRACT

Although the main cause of gastrointestinal stromal tumor (GIST) is gain-of-function mutations in the c-kit gene in the interstitial cells of Cajal, concomitant genetic or epigenetic changes other than c-kit appear to occur in the development of metastasis. We sought to identify the genes involved in the metastatic process of gastric GIST. Microarray analysis was performed to compare gene expressions between three gastric GIST and four metastatic liver GIST. Expression levels were higher for 165 genes and lower for 146 genes in metastatic liver GIST. The upregulation of five oncogenes and downregulation of four tumor suppressor genes including versican and CD9 were confirmed by quantitative reverse transcriptional PCR. Immunohistochemistry in 117 GIST revealed that protein levels of versican and CD9 were higher and lower, respectively, in metastatic GIST. High expression of versican and low expression of CD9 in 104 primary gastric GIST correlated with poor disease-free survival (P = 0.0078 and P = 0.0018). In addition to the c-kit gene mutation, genetic or epigenetic changes other than c-kit play important roles in the metastatic process. In particular, versican and CD9 are potential prognostic markers in gastric GIST.


Subject(s)
Antigens, CD/genetics , Biomarkers, Tumor/genetics , Gastrointestinal Stromal Tumors/genetics , Gene Expression Profiling , Liver Neoplasms/genetics , Membrane Glycoproteins/genetics , Stomach Neoplasms/genetics , Versicans/genetics , Adult , Aged , Antigens, CD/metabolism , Biomarkers, Tumor/metabolism , Female , Gastric Mucosa/metabolism , Gastrointestinal Stromal Tumors/metabolism , Gastrointestinal Stromal Tumors/pathology , Humans , Immunoenzyme Techniques , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Male , Membrane Glycoproteins/metabolism , Mutation/genetics , Oligonucleotide Array Sequence Analysis , Prognosis , Proto-Oncogene Proteins c-kit/genetics , Proto-Oncogene Proteins c-kit/metabolism , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Survival Rate , Tetraspanin 29 , Versicans/metabolism
7.
J Clin Pharmacol ; 51(7): 1079-86, 2011 Jul.
Article in English | MEDLINE | ID: mdl-20663999

ABSTRACT

The preventive effects of lansoprazole and famotidine on low-dose aspirin-induced gastric mucosal injury in relation to gastric acidity were compared in healthy Japanese volunteers. Fifteen Helicobacter pylori-negative volunteers with different CYP2C19 genotypes were randomly administered aspirin 100 mg, aspirin plus famotidine 20 mg twice daily, or aspirin plus lansoprazole 15 mg once daily for 7 days each in a crossover fashion. Gastroscopy for the evaluation of mucosal injury based on modified Lanza score (MLS) and 24-hour intragastric pH monitoring were performed on day 7 of each regimen. Aspirin induced gastric mucosal injury (median MLS = 3). Lansoprazole significantly decreased MLS to 0, which was significantly lower than that by famotidine (MLS = 1) (P < .05). Medians of pH 3 holding time and mean 24-hour pH values with the lansoprazole regimen were significantly higher than those with famotidine (P < .05). No significant differences in MLS were observed among the different CYP2C19 genotype groups in any of the treatment regimens. In this 7-day study, lansoprazole appeared to be more protective than famotidine against low-dose aspirin-induced mucosal injury but a larger well-controlled study is necessary to establish a definitive clinical benefit.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Anti-Ulcer Agents/therapeutic use , Famotidine/therapeutic use , Gastric Mucosa/drug effects , Histamine H2 Antagonists/therapeutic use , Proton Pump Inhibitors , Stomach Ulcer/prevention & control , 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Anti-Ulcer Agents/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Aspirin/administration & dosage , Aspirin/toxicity , Cross-Over Studies , Cytochrome P-450 CYP2C19 , Famotidine/administration & dosage , Female , Gastric Acidity Determination , Gastric Mucosa/pathology , Genotype , Histamine H2 Antagonists/administration & dosage , Humans , Japan , Lansoprazole , Male , Severity of Illness Index , Stomach Ulcer/chemically induced , Stomach Ulcer/genetics , Stomach Ulcer/pathology , Young Adult
8.
J Clin Pharmacol ; 50(3): 320-30, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19940233

ABSTRACT

Aspirin is used widely as an antithrombotic drug for the prevention of cardiovascular and cerebrovascular events. Although aspirin increases the risk for gastrointestinal mucosal injury, the effect on esophageal mucosa is unclear. This study investigates whether aspirin induces esophageal mucosal injury and whether a proton-pump inhibitor can prevent such injury in relation to CYP2C19 genotypes. Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day. All subjects undergo endoscopy and 24-hour intragastric pH monitoring on day 7. With the aspirin regimen, esophageal mucosal disorders occur in 7 patients (46.7%) (5, grade M; 2, grade A). The median 24-hour pH differs significantly among subjects who develop grade M or A gastroesophageal reflux disease and those who do not develop gastroesophageal reflux disease; the median pH in grade A gastroesophageal reflux disease is significantly lower (1.5 [range, 1.1-1.9]) than that in patients without gastroesophageal reflux disease (5.6 [range, 0.8-8.4], P = .04). Rabeprazole significantly inhibits acid secretion irrespective of CYP2C19 genotypes and decreases the incidence of aspirin-related esophageal injury and symptoms according to increasing pH value. Aspirin induces esophageal mucosal injury in an acid-dependent manner. Concomitant proton-pump inhibitor therapy may prevent advanced effects of low-dose aspirin.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Ulcer Agents/therapeutic use , Aspirin/adverse effects , Esophagitis, Peptic/chemically induced , Esophagitis, Peptic/prevention & control , Gastric Mucosa/drug effects , Gastroesophageal Reflux/chemically induced , Gastroesophageal Reflux/prevention & control , Platelet Aggregation Inhibitors/adverse effects , 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , Administration, Oral , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Ulcer Agents/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Asian People , Aspirin/administration & dosage , Cross-Over Studies , Cytochrome P-450 CYP2C19 , DNA , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Esophageal pH Monitoring , Esophagitis, Peptic/physiopathology , Esophagoscopy , Female , Gastric Mucosa/metabolism , Gastroesophageal Reflux/physiopathology , Genotype , Heartburn/chemically induced , Heartburn/prevention & control , Humans , Japan , Male , Mutation , Platelet Aggregation Inhibitors/administration & dosage , Rabeprazole , Young Adult
9.
Dig Dis Sci ; 55(6): 1627-36, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19672708

ABSTRACT

BACKGROUND AND AIMS: Gastric acid plays an important role in the pathogenesis of gastric mucosal lesions. We investigated whether aspirin-induced gastric mucosal injury might have any association with the intragastric pH. MATERIALS AND METHODS: Fifteen healthy, Helicobacter pylori-negative volunteers randomly underwent the four different 7-day regimens: (1) aspirin 100 mg, (2) rabeprazole 10 mg, (3) aspirin 100 mg + rabeprazole 10 mg, and (4) aspirin 100 mg + rabeprazole 40 mg. Gastric mucosal injury based on the modified Lanza score (MLS), 24-h intragastric pH, and histopathology of gastric mucosa were evaluated prior to the start and on day 7 of each regimen. RESULTS: The median MLSs were 0 in the baseline and the rabeprazole 10 mg regimen. The median MLS in the aspirin regimen was 3, while those in both aspirin + rabeprazole 10 mg and aspirin + rabeprazole 40 mg regimens were 0. Rabeprazole significantly prevented the gastric mucosal injury by aspirin (P = 0.001 for rabeprazole 10 mg and P = 0.005 for rabeprazole 40 mg). The MLSs were negatively correlated with the 24-h intragastric pH (P = -0.711, < 0.001), whereas aspirin had no effect on the intragastric pH. Aspirin expanded the mean diameter of the microvessels of the gastric mucosa, which, in turn, was negatively correlated with the intragastric pH. CONCLUSIONS: Aspirin might induce gastric mucosal injury by affecting the mucosal microvessels in an acid-dependent manner. Sustained maintenance of the intragastric pH at an elevated value is necessary to prevent gastric mucosal damage induced by aspirin.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Aspirin/adverse effects , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Proton Pump Inhibitors/administration & dosage , Stomach Ulcer/prevention & control , 2-Pyridinylmethylsulfinylbenzimidazoles/metabolism , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Aryl Hydrocarbon Hydroxylases/metabolism , Aspirin/administration & dosage , Biopsy , Cytochrome P-450 CYP2C19 , Female , Gastric Acidity Determination , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Gastroscopy , Genotype , Humans , Hydrogen-Ion Concentration , Male , Phenotype , Proton Pump Inhibitors/metabolism , Rabeprazole , Severity of Illness Index , Stomach Ulcer/chemically induced , Stomach Ulcer/metabolism , Stomach Ulcer/pathology , Young Adult
10.
Surg Today ; 39(12): 1046-53, 2009.
Article in English | MEDLINE | ID: mdl-19997799

ABSTRACT

PURPOSE: Combination therapy using antiangiogenic and cytotoxic agents is a useful strategy for advanced cancer, but the mechanism has not yet been elucidated. Moreover, there is a persistent paradox that destroying tumor vasculature with antiangiogenic agents disturbs the delivery of cytotoxic agents. It has been hypothesized that antiangiogenic agents can lead to normalization of tumor vessels that are structurally and functionally abnormal. The normalization means enhancing the deliver of cytotoxic agents. Our purpose was to investigate whether TSU68, a multiple receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), would induce the normalization of tumor vessels. METHODS: TSU68 was administered for 7 days to mice with xenografted tumors. Tumors of interstitial fluid pressure (IFP) were measured before and after administration of agents. Immunofluorescence double staining for CD31 and alpha-SMA was performed, and a medical video endoscopy system with narrowband illumination (NBI) was used to visualize the vascular pattern. RESULTS: TSU68 treatment decreased IFP significantly. Immunofluorescence double staining showed a significant increase in the fraction of pericyte coverage in the TSU68-treated group. NBI endoscopy showed that many tumor vessels in TSU68-treated mice were pruned and the diameters of remaining vessels were reduced. CONCLUSION: The data supported our hypothesis of tumor vascular normalization by the antiangiogenic agent TSU68.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Colon/blood supply , Colonic Neoplasms/drug therapy , Indoles/pharmacology , Neovascularization, Pathologic/prevention & control , Neovascularization, Physiologic/physiology , Propionates/pharmacology , Animals , Colon/pathology , Colonic Neoplasms/pathology , Disease Models, Animal , Drug Delivery Systems/methods , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Neovascularization, Physiologic/drug effects , Oxindoles , Pyrroles , Receptors, Fibroblast Growth Factor/drug effects , Receptors, Fibroblast Growth Factor/metabolism , Receptors, Platelet-Derived Growth Factor/drug effects , Receptors, Platelet-Derived Growth Factor/metabolism , Sensitivity and Specificity , Transplantation, Heterologous , Vascular Endothelial Growth Factor Receptor-2/drug effects , Vascular Endothelial Growth Factor Receptor-2/metabolism , Xenograft Model Antitumor Assays
11.
J Neurochem ; 109(2): 393-402, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19200342

ABSTRACT

In order to examine the possible involvements of Ca(2+)/calmodulin-dependent protein kinases (CaM kinases) in the regulation of ribosomal functions, we tested the phosphorylation of rat ribosomal protein S19 (RPS19) by various CaM kinases in vitro. We found that CaM kinase Ialpha, but not CaM kinase Ibeta1, Ibeta2, II, or IV, robustly phosphorylated RPS19. From the consensus phosphorylation site sequence, Ser59, Ser90, and Thr124 were likely to be phosphorylated; therefore, we mutated each amino acid to alanine and found that the mutation of Ser59 to alanine strongly attenuated phosphorylation by CaM kinase Ialpha, suggesting that Ser59 was a major phosphorylation site. Furthermore, we produced a specific antibody against RPS19 phosphorylated at Ser59, and found that Ser59 was phosphorylated both in GT1-7 cells and rat brain. Phosphorylation of RPS19 in GT1-7 cells was inhibited by KN93, an inhibitor of CaM kinases. Immunoblot analysis after subcellular fractionation of rat brain demonstrated that phosphorylated RPS19 was present in 80S ribosomes. Phosphorylation of RPS19 by CaM kinase Ialpha augmented the interaction of RPS19 with the previously identified S19 binding protein. These results suggest that CaM kinase Ialpha regulates the functions of RPS19 through phosphorylation of Ser59.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 1/metabolism , Drosophila Proteins/metabolism , Ribosomal Proteins/metabolism , Serine/metabolism , Animals , Cell Line, Transformed , Phosphorylation , Protein Subunits/metabolism , Rats
12.
Cancer Res ; 68(23): 9754-62, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-19047154

ABSTRACT

The aim of this study was to investigate the inhibitory effect of TSU68 [(Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid; SU6668], an inhibitor of vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor beta, and fibroblast growth factor receptor 1 (FGFR1), on colon cancer liver metastasis, and to test the hypothesis that TSU68 modulates the microenvironment in the liver before the formation of metastasis. First, we implanted the highly metastatic human colon cancer TK-4 orthotopically into the cecal walls of nude mice, followed by twice-daily administration of TSU68 (400 mg/kg/d) or vehicle. Five weeks of treatment with TSU68 significantly inhibited liver metastasis compared with the control group (P<0.001). Next, we analyzed the gene expression profile in premetastatic liver using microarrays. Microarray and quantitative reverse transcription-PCR analysis showed that mRNA levels for the chemokine CXCL1 were significantly increased in tumor-bearing mice compared with non-tumor-bearing mice. Moreover, CXCL1 expression was significantly decreased by TSU68 treatment. CXCR2 expression was detected predominantly on tumor cells in orthotopic tumors compared with ectopic tumors. The number of migrating neutrophils in premetastatic liver was significantly decreased in the TSU68-treated group (P<0.001). The amount of interleukin-12 (IL-12) p40 in the portal vein was significantly decreased by TSU68 (P=0.02). Blockade of both CXCR2 and IL-12 p40 with a neutralizing antibody significantly inhibited liver metastasis. These results suggest that the CXCL1/CXCR2 axis is important in cancer metastasis and that TSU68 may modulate the premetastatic niche in the target organ through suppression of the inflammatory response, which might be an alternative mechanism used by antiangiogenic agents.


Subject(s)
Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , Indoles/pharmacology , Liver Neoplasms, Experimental/prevention & control , Liver Neoplasms, Experimental/secondary , Propionates/pharmacology , Animals , Cell Movement/immunology , Chemokine CXCL1/biosynthesis , Chemokine CXCL1/genetics , Colonic Neoplasms/genetics , Colonic Neoplasms/immunology , Gene Expression Profiling , Humans , Interleukin-12 Subunit p40/antagonists & inhibitors , Interleukin-12 Subunit p40/immunology , Liver/blood supply , Liver/physiopathology , Liver Neoplasms, Experimental/genetics , Liver Neoplasms, Experimental/immunology , Male , Mice , Mice, Inbred BALB C , Neutrophils/immunology , Neutrophils/pathology , Oligonucleotide Array Sequence Analysis , Oxindoles , Pyrroles , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Interleukin-8B/antagonists & inhibitors , Receptors, Interleukin-8B/biosynthesis , Receptors, Interleukin-8B/genetics , Xenograft Model Antitumor Assays
13.
Anticancer Res ; 28(2A): 693-8, 2008.
Article in English | MEDLINE | ID: mdl-18507009

ABSTRACT

Antitumor effects of plasminogen activator (PA) inhibitors (PAls) were analyzed in a mouse model of human colon cancer xenografts. Either recombinant PA inhibitor-1 (rPAI-1) or inhibitor-2 (rPAI-2) was injected intraperitoneally to nude mice bearing human colon cancer xenografts for 6 weeks. Primary tumors in rPAI-2-treated group were smaller (0.45 +/- 0.13 g, n = 16) than in the other two groups (control: 0.73 +/- 0.24 g, n = 15; rPAI-1: 0.62 +/- 0.29 g, n = 19). Primary tumors in the rPAI-2-treated group exhibited less mature ductal structures and were significantly smaller. The apoptotic index was higher in the rPAI-2-treated group (4.64 +/- 2.12%) than in the other groups (control: 1.94 +/- 0.82%; rPAI-1: 2.08 +/- 1.07%). Liver metastasis was less frequent in the rPAI-1 (5/19) and rPAI-2-treated groups (1/16) than in the control group (14/15). PAI-2 more effectively suppressed tumor metastasis and progression, probably by inducing apoptosis; some different unknown mechanism may cause the difference in both antitumor effect and the histological findings. This may indicate the therapeutic potential of these PAls in malignant patients.


Subject(s)
Apoptosis/drug effects , Colonic Neoplasms/drug therapy , Liver Neoplasms/secondary , Plasminogen Activator Inhibitor 2/pharmacology , Animals , Drug Evaluation , Humans , Infusions, Parenteral , Liver Neoplasms/prevention & control , Mice , Mice, Inbred BALB C , Mice, Nude , Plasminogen Activator Inhibitor 2/administration & dosage , Recombinant Proteins/pharmacology , Xenograft Model Antitumor Assays
14.
Chem Pharm Bull (Tokyo) ; 56(5): 692-4, 2008 May.
Article in English | MEDLINE | ID: mdl-18451560

ABSTRACT

Silver loaded zeolite (Ag-Z) was previously found to have effective bactericidal activity against Escherichia coli. To understand the mechanisms of bactericidal activity of Ag-Z, role of light irradiation was focused and investigated in this study. In this study, we focused on light irradiation. Antibacterial assay and spectroscopic study revealed that light irradiation enabled Ag-Z to reduce dioxygen to form a reactive oxygen species, which led to bactericidal activity. These results indicate that the onset of bactericidal activity can be controlled by light irradiation.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/radiation effects , Bacteria/drug effects , Bacteria/radiation effects , Silver/pharmacology , Silver/radiation effects , Zeolites/pharmacology , Zeolites/radiation effects , Anti-Bacterial Agents/chemistry , Bacteria/enzymology , Colony Count, Microbial , Cytochromes c/metabolism , Electron Spin Resonance Spectroscopy , Escherichia coli/drug effects , Escherichia coli/radiation effects , Light , Oxygen/chemistry , Oxygen/radiation effects , Reactive Oxygen Species/metabolism , Silver/chemistry , Spectrophotometry, Ultraviolet , Zeolites/chemistry
15.
J Gastroenterol ; 43(4): 283-90, 2008.
Article in English | MEDLINE | ID: mdl-18458844

ABSTRACT

BACKGROUND: Gastric cancer is one of the most common cancers in Japan. The use of endoscopy is increasing, along with the number of histological examinations of specimens obtained by endoscopy. However, it takes several days to reach a diagnosis, which increases the medical expense. Raman spectroscopy is one of the available optical techniques, and the Raman spectrum for each molecule and tissue is characteristic and specific. The present study investigated whether Raman spectroscopy can be used to diagnose gastric cancer. METHODS: A total of 251 fresh biopsy specimens of gastric carcinoma and non-neoplastic mucosa were obtained from 49 gastric cancer patients at endoscopy. Without any pretreatment, the fresh specimens were measured with a near-infrared multichannel Raman spectroscopic system with an excitation wavelength of 1064 nm, and Raman spectra specific for the specimens were obtained. A principal component analysis (PCA) was performed to distinguish gastric cancer and non-neoplastic tissue, and a discriminant analysis was used to evaluate the accuracy of the gastric cancer diagnosis. RESULTS: The Raman spectra for cancer specimens differed from those for non-neoplastic specimens, especially at around 1644 cm(-1). Sensitivity was 66%, specificity was 73%, and accuracy was 70%. The accuracy of diagnosis using the single Raman scattering intensity at 1644 cm(-1) was 70%, consistent with the PCA result. CONCLUSIONS: The present results indicate that near-infrared multichannel Raman spectroscopy with a 1064-nm excitation wavelength is useful for gastric cancer diagnosis. Establishment of a Raman diagnostic system for gastric cancer may improve the clinical diagnosis of gastric cancer and be beneficial for patients.


Subject(s)
Carcinoma/diagnosis , Gastric Mucosa/pathology , Spectrum Analysis, Raman/methods , Stomach Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biopsy , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Lasers, Solid-State , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity
16.
Cancer Sci ; 98(11): 1734-9, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17894554

ABSTRACT

The authors have previously reported that loss of heterozygosity (LOH) of the c-kit gene could be responsible for the gain in high proliferative activity in some gastrointestinal stromal tumors (GIST), resulting in enhanced metastatic potential. In the present study, an attempt was made to identify the factors that might predict the postoperative prognosis of patients with metastatic liver GIST. The clinicopathologic or genetic features of resected liver GIST in 14 patients who had undergone a hepatectomy for metachronous liver metastases and who had not received adjuvant imatinib treatment were examined. LOH of the c-kit gene was observed in seven of 12 metastatic liver GIST (58.3%), of which DNA suitable for testing could be extracted. Ten patients had recurrence after hepatectomy and four had none. The median post-recurrent disease-free survival (PRDFS) after hepatectomy was 27.5 months (range 8-104). The tumor-specific PRDFS was examined using clinicopathologic features, c-kit mutation and LOH of the c-kit gene. No single clinicopathologic or genetic finding was significantly associated with PRDFS. However, patients with 'Ki67 labeling index <5% and LOH(-)' had a significantly longer PRDFS than those with 'Ki67 >/=5% or LOH(+)' (P = 0.032), and there was no correlation between the presence of LOH of the c-kit gene and the Ki67 labeling index. LOH of the c-kit gene in metastatic liver seems to be a common event, and LOH of the c-kit gene in resected liver GIST may be a helpful factor in the prediction of the post-recurrent prognosis of patients with liver metastasis.


Subject(s)
Gastrointestinal Stromal Tumors/genetics , Gastrointestinal Stromal Tumors/surgery , Hepatectomy , Liver Neoplasms/genetics , Liver Neoplasms/surgery , Loss of Heterozygosity , Proto-Oncogene Proteins c-kit/genetics , Aged , DNA Mutational Analysis , DNA, Neoplasm/genetics , DNA, Neoplasm/isolation & purification , Exons , Female , Gastrointestinal Stromal Tumors/pathology , Humans , Immunohistochemistry , Liver Neoplasms/pathology , Male , Microsatellite Repeats , Middle Aged , Neoplasm Metastasis , Polymerase Chain Reaction , Prognosis , Treatment Outcome
17.
Cancer Res ; 66(24): 11623-31, 2006 Dec 15.
Article in English | MEDLINE | ID: mdl-17178856

ABSTRACT

A reduced expression level of the cyclin-dependent kinase inhibitor p27(Kip1) is associated with increased tumor malignancy and poor prognosis in individuals with various types of cancer. To investigate the basis for this relation, we applied microarray analysis to screen for genes differentially expressed between p27(+/-) and parental (p27(+/+)) HCT116 human colon carcinoma cells. Expression of the gene for G protein-coupled receptor 48 (GPR48) was increased in the p27(+/-) cells. Forced expression of GPR48 increased both in vitro invasive activity and lung metastasis potency of HCT116 cells. In contrast, depletion of endogenous GPR48 by RNA interference reduced the invasive potential of HeLa and Lewis lung carcinoma cells not only in vitro but also in vivo. Moreover, GPR48 expression was significantly associated with lymph node metastasis and inversely correlated with p27 expression in human colon carcinomas. GPR48 may thus play an important role in invasiveness and metastasis of carcinoma and might therefore represent a potential prognostic marker or therapeutic target.


Subject(s)
Gene Expression Regulation, Neoplastic , Intracellular Signaling Peptides and Proteins/genetics , Neoplasm Invasiveness/genetics , Receptors, G-Protein-Coupled/genetics , Animals , Cell Line , Cell Line, Tumor , Colonic Neoplasms , Cyclin-Dependent Kinase Inhibitor p27 , DNA Primers , Fibroblasts/physiology , Genes, Reporter , HeLa Cells , Humans , Luciferases/genetics , Mice , Neoplasm Metastasis/genetics , Oligonucleotide Array Sequence Analysis , Proliferating Cell Nuclear Antigen/genetics , RNA Interference , Reverse Transcriptase Polymerase Chain Reaction
18.
Nihon Shokakibyo Gakkai Zasshi ; 103(9): 1055-60, 2006 Sep.
Article in Japanese | MEDLINE | ID: mdl-16953103

ABSTRACT

A 58-year-old Japanese man underwent partial gastrectomy in 1991 for a tumor showing extra-gastric growth measuring 18 x 16.5 x 8.8 cm in size. An immunohistochemical study yielded a diagnosis of gastric GIST with few mitoses. In 2004, abdominal CT showed a solitary liver metastasis without extrahepatic recurrence and right hepatic lobectomy was performed. No adjuvant treatment has been done and he is alive without recurrence 1 year after the hepatectomy. Long term follow-up of more than 10 years is required after resection of primary tumors if they are diagnosed as high risk GISTs with few mitoses.


Subject(s)
Gastrectomy , Gastrointestinal Stromal Tumors/secondary , Gastrointestinal Stromal Tumors/surgery , Liver Neoplasms/secondary , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Hepatectomy , Humans , Liver Neoplasms/surgery , Male , Middle Aged , Postoperative Period , Time Factors
19.
World J Gastroenterol ; 12(21): 3393-9, 2006 Jun 07.
Article in English | MEDLINE | ID: mdl-16733857

ABSTRACT

AIM: To investigate the relationship between ulcerative colitis (UC) clinical activity index (CAI) and circulating levels of IL-1ra, IL-10, IL-6 and IL-18. METHODS: Blood levels of IL-1ra, IL-10, IL-6 and IL-18 were measured in 31 patients with active UC, the mean CAI was 11.1, ranging from 5-25; and 12 healthy individuals as controls. Patients were given granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn. Leucocytes which bear the FcgammaR and complement receptors were adsorbed to the column leucocytapheresis carriers. Each patient could receive up to 11 GMA sessions over 8 wk. RESULTS: We found strong correlations between CAI and IL-10 (r = 0.827, P < 0.001), IL-6 (r = 0.785, P < 0.001) and IL-18 (r = 0.791, P < 0.001). IL-1ra was not correlated with CAI. Following GMA therapy, 24 of the 31 patients achieved remission and the levels of all 4 cytokines fell to the levels in healthy controls. Further, blood levels of IL-1ra and IL-10 increased at the column outflow and inflow at 60 min suggesting release from leucocytes that adhered to the carriers.


Subject(s)
Colitis, Ulcerative/blood , Colitis, Ulcerative/immunology , Cytokines/blood , Interleukins/blood , Leukapheresis/methods , Adolescent , Adult , Blood Cell Count , Colitis, Ulcerative/therapy , Cytokines/physiology , Female , Granulocytes/pathology , Granulocytes/physiology , Humans , Inflammation/blood , Inflammation/physiopathology , Macrophages/pathology , Macrophages/physiology , Male , Middle Aged , Monocytes/pathology , Monocytes/physiology , Severity of Illness Index
20.
Cancer Sci ; 97(2): 127-32, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16441423

ABSTRACT

Metastatic gastrointestinal stromal tumors (GIST) have an extremely poor prognosis; however, their immunohistochemical and genetic features have not been assessed satisfactorily and the mechanisms responsible for their high malignant potential remain unclear. We examined the immunohistochemical differences between gastric GIST and metastatic lesions in the liver of four patients who had undergone a postgastrectomy hepatectomy for metachronous liver metastases. We also carried out genetic analysis of the tumors in three of the four cases. In all cases, the immunoreactivity profiles, including KIT (CD117), CD34, smooth muscle actin (SMA), desmin, S-100 and vimentin, were similar between the gastric and metastatic tumors, but the Ki67 labeling index in the metastatic GIST was higher than that of the primary GIST. Interestingly, in the case who had received neoadjuvant imatinib therapy before gastrectomy, its therapeutic effect was observed in most of the primary lesion, with the exception of a specific small area with high cellularity. Genetic analysis revealed no acquired mutations in the c-kit or PDGFRA genes in the metastatic lesions in any of the patients, but loss of heterozygosity (LOH) of the c-kit gene was observed mainly in the metastatic tumors in two of the three cases. Furthermore, in the case of neoadjuvant imatinib therapy, LOH of the c-kit gene was shown in the high cellularity area in the primary lesion and metastatic liver GIST. It is suggested that LOH of the c-kit gene is an important event that leads to imatinib resistance and metastatic progression of GIST. In conclusion, both gastric and metastatic GIST had almost the same immunohistochemical features, except for their proliferative activity, and LOH of the c-kit gene played an important role in the process of liver metastasis.


Subject(s)
Gastrointestinal Stromal Tumors/genetics , Liver Neoplasms/genetics , Neoplasm Proteins/metabolism , Proto-Oncogene Proteins c-kit/genetics , Stomach Neoplasms/genetics , Aged , Amino Acid Sequence , Antineoplastic Agents/therapeutic use , Benzamides , Female , Gastrointestinal Stromal Tumors/metabolism , Gastrointestinal Stromal Tumors/secondary , Humans , Imatinib Mesylate , Immunoenzyme Techniques , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Loss of Heterozygosity , Male , Microsatellite Repeats , Middle Aged , Molecular Sequence Data , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Sequence Homology, Amino Acid , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...